摘要
轉移性大腸直腸癌的治療方式包括化學治療、分子標靶治療、及手術治療。常用的化學治療處方為irinotecan或oxaliplatin與fluoropyrimidine組合的FOLFOX或FOLFIRI，近年來以口服的capecitabine搭配oxaliplatin的XELOX組合，初步研究也有很好的成效。分子標靶治療主要是利用anti-VEGF或anti-EGFR的單株抗體，可單獨使用或與化學治療適當組合。少數肝轉移的病人，可藉由手術切除得到長期控制，且化學治療後才能切除的腫瘤，其存活率與可以直接切除者相當。由於這些治療方式的進步，目前轉移性大腸直腸癌的中位存活率已達到二年以上。
並列摘要
Treatment of metastatic colorectal cancer metastasis includes chemotherapy, targeted therapy and surgery. Common chemotherapy regimens are FOLFOX or FOLFIRI composed of fluoropyrimidine plus irinotecan or oxaliplatin. Recently, studies have reported promising results with XELOX (capecitabine plus oxaliplatin). In addition, molecular targeted therapy using anti-VEGF or anti-EGFR monoclonal antibodies can be administered alone or combined with chemotherapy. In a subset of patients with hepatic metastases, long-term survival can be achieved by curative surgical resection. Moreover, survival rates of the patients with metastatic disease which becomes resectable after neoadjuvant chemotherapy, are comparable to those who present with initially resectable metastasis. Because of advances in these treatment modalities, the reported median survival of the patients with colorectal cancer metastasis has been longer than two years.
被引用紀錄
延伸閱讀
- 曾斐祺（2020）。大腸直腸癌的治療與照護。腫瘤護理雜誌，20(2)，5-9。https://doi.org/10.6880/TJON.202012_20(2).01
- 廖御佐、梁金銅（2018）。轉移性大腸直腸癌的化學治療、標靶治療與免疫療法的近期回顧。臺灣醫界，61(10)，18-26。https://www.airitilibrary.com/Article/Detail?DocID=17263603-201810-201811160005-201811160005-18-26
- 白雪翠、楊逸文（2023）。早期直腸癌的治療。臨床醫學月刊，91(4)，208-209。https://doi.org/10.6666/ClinMed.202304_91(4).0037
- 中華景康藥學基金會（2017）。大腸癌治療方式。健康世界，(488)，47-49。https://www.airitilibrary.com/Article/Detail?DocID=16077059-201708-201709110009-201709110009-47-49
- 邱瀚模（2008）。Screening, Diagnosis and Treatment of Early Colorectal Cancer。中華民國癌症醫學會雜誌，24(3)，148-156。https://doi.org/10.6588/JCOS.2008.24.3.2